Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 54

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Targeting calcium regulators as therapy for heart failure: focus on the sarcoplasmic reticulum Ca-ATPase pump

Kho, Changwon · 2023 · Frontiers in Cardiovascular Medicine

Abstract

Impaired myocardial Ca 2+ cycling is a critical contributor to the development of heart failure (HF), causing changes in the contractile function and structure remodeling of the heart. Within cardiomyocytes, the regulation of sarcoplasmic reticulum (SR) Ca 2+ storage and release is largely dependent on Ca 2+ handling proteins, such as the SR Ca 2+ ATPase (SERCA2a) pump. During the relaxation phase of the cardiac cycle (diastole), SERCA2a plays a critical role in transporting cytosolic Ca 2+ back to the SR, which helps to restore both cytosolic Ca 2+ levels to their resting state and SR Ca 2+ content for the next contraction. However, decreased SERCA2a expression and/or pump activity are key features in HF. As a result, there is a growing interest in developing therapeutic approaches to target SERCA2a. This review provides an overview of the regulatory mechanisms of the SERCA2a pump and explores potential strategies for SERCA2a-targeted therapy, which are being investigated in both preclinical and clinical studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fcvm.2023.1185261

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 140

  1. Disease, 2018, Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017, Lancet, 392, 1789, 10.1016/S0140-6736(18)32279-7 · DOI · Paper page
  2. Hasenfuss, 1992, Alteration of contractile function and excitation-contraction coupling in dilated cardiomyopathy, Circ Res, 70, 1225, 10.1161/01.res.70.6.1225 · DOI · Paper page
  3. Beuckelmann, 1992, Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure, Circulation, 85, 1046, 10.1161/01.cir.85.3.1046 · DOI · Paper page
  4. Gwathmey, 1987, Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure, Circ Res, 61, 70, 10.1161/01.res.61.1.70 · DOI · Paper page
  5. Mercadier, 1990, Altered sarcoplasmic reticulum Ca2(+)-ATPase gene expression in the human ventricle during end-stage heart failure, J Clin Invest, 85, 305, 10.1172/JCI114429 · DOI · Paper page
  6. Arai, 1993, Alterations in sarcoplasmic reticulum gene expression in human heart failure. A possible mechanism for alterations in systolic and diastolic properties of the failing myocardium, Circ Res, 72, 463, 10.1161/01.res.72.2.463 · DOI · Paper page
  7. Takahashi, 1992, Expression of A-, B-, and C-type natriuretic peptide genes in failing and developing human ventricles. Correlation with expression of the Ca(2+)-ATPase gene, Circ Res, 71, 9, 10.1161/01.res.71.1.9 · DOI · Paper page
  8. Bers, 2002, Cardiac excitation-contraction coupling, Nature, 415, 198, 10.1038/415198a · DOI · Paper page
  9. Hove-Madsen, 1993, Sarcoplasmic reticulum Ca2+ uptake and thapsigargin sensitivity in permeabilized rabbit and rat ventricular myocytes, Circ Res, 73, 820, 10.1161/01.res.73.5.820 · DOI
  10. Periasamy, 1999, Impaired cardiac performance in heterozygous mice with a null mutation in the sarco(endo)plasmic reticulum Ca2+-ATPase isoform 2 (SERCA2) gene, J Biol Chem, 274, 2556, 10.1074/jbc.274.4.2556 · DOI · Paper page
  11. Huke, 2003, Altered force-frequency response in non-failing hearts with decreased SERCA pump-level, Cardiovasc Res, 59, 668, 10.1016/s0008-6363(03)00436-x · DOI
  12. Andersson, 2009, Moderate heart dysfunction in mice with inducible cardiomyocyte-specific excision of the Serca2 gene, J Mol Cell Cardiol, 47, 180, 10.1016/j.yjmcc.2009.03.013 · DOI
  13. Louch, 2010, Sodium accumulation promotes diastolic dysfunction in end-stage heart failure following Serca2 knockout, J Physiol, 588, 465, 10.1113/jphysiol.2009.183517 · doi:10.1113/jphysiol.2009.183517
  14. Studer, 1994, Gene expression of the cardiac Na(+)-Ca2+ exchanger in end-stage human heart failure, Circ Res, 75, 443, 10.1161/01.res.75.3.443 · DOI · Paper page
  15. Hasenfuss, 1994, Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium, Circ Res, 75, 434, 10.1161/01.res.75.3.434 · DOI · Paper page
  16. Venetucci, 2008, The sarcoplasmic reticulum and arrhythmogenic calcium release, Cardiovasc Res, 77, 285, 10.1093/cvr/cvm009 · DOI · Paper page
  17. Lyon, 2009, Loss of T-tubules and other changes to surface topography in ventricular myocytes from failing human and rat heart, Proc Natl Acad Sci U S A, 106, 6854, 10.1073/pnas.0809777106 · DOI · Paper page
  18. O'Neill, 2004, Interplay between SERCA and sarcolemmal Ca2+ efflux pathways controls spontaneous release of Ca2+ from the sarcoplasmic reticulum in rat ventricular myocytes, J Physiol, 559, 121, 10.1113/jphysiol.2003.058917 · DOI
  19. Fernandez-Tenorio, 2018, Stabilization of Ca2+ signaling in cardiac muscle by stimulation of SERCA, J Mol Cell Cardiol, 119, 87, 10.1016/j.yjmcc.2018.04.015 · DOI
  20. van der Zwaag, 2012, Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy, Eur J Heart Fail, 14, 1199, 10.1093/eurjhf/hfs119 · DOI · Paper page
  21. Haghighi, 2006, A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy, Proc Natl Acad Sci U S A, 103, 1388, 10.1073/pnas.0510519103 · DOI · Paper page
  22. Kawase, 2008, Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure, J Am Coll Cardiol, 51, 1112, 10.1016/j.jacc.2007.12.014 · DOI · Paper page
  23. del Monte, 1999, Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a, Circulation, 100, 2308, 10.1161/01.cir.100.23.2308 · DOI · Paper page
  24. Packer, 1991, Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE study research group, N Engl J Med, 325, 1468, 10.1056/NEJM199111213252103 · DOI · Paper page
  25. Motloch, 2018, Primary effect of SERCA 2a gene transfer on conduction reserve in chronic myocardial infarction, J Am Heart Assoc, 7, e009598, 10.1161/JAHA.118.009598 · DOI
  26. Prunier, 2008, Prevention of ventricular arrhythmias with sarcoplasmic reticulum Ca2+ ATPase pump overexpression in a porcine model of ischemia reperfusion, Circulation, 118, 614, 10.1161/CIRCULATIONAHA.108.770883 · DOI
  27. del Monte, 2001, Overwhelming evidence of the beneficial effects of SERCA gene transfer in heart failure, Circ Res, 88, E66, 10.1161/hh1101.092004 · DOI
  28. Studeli, 2006, Diastolic dysfunction in human cardiac allografts is related with reduced SERCA2a gene expression, Am J Transplant, 6, 775, 10.1111/j.1600-6143.2006.01241.x · DOI
  29. Lim, 1999, Impaired lusitropy-frequency in the aging mouse: role of Ca(2+)-handling proteins and effects of isoproterenol, Am J Physiol, 277, H2083, 10.1152/ajpheart.1999.277.5.H2083 · DOI
  30. Belke, 2004, Decreased sarcoplasmic reticulum activity and contractility in diabetic db/db mouse heart, Diabetes, 53, 3201, 10.2337/diabetes.53.12.3201 · DOI · Paper page
  31. Torre, 2022, SERCA2a Stimulation by istaroxime improves intracellular Ca2+ handling and diastolic dysfunction in a model of diabetic cardiomyopathy, Cardiovasc Res, 118, 1020, 10.1093/cvr/cvab123 · DOI
  32. Wankerl, 1996, Molecular cloning and analysis of the human cardiac sarco(endo)plasmic reticulum Ca(2+)-ATPase (SERCA2) gene promoter, J Mol Cell Cardiol, 28, 2139, 10.1006/jmcc.1996.0206 · doi:10.1006/jmcc.1996.0206
  33. Zarain-Herzberg, 2002, Sarco(endo)plasmic reticulum Ca2+-ATPase-2 gene: structure and transcriptional regulation of the human gene, ScientificWorldJournal, 2, 1469, 10.1100/tsw.2002.228 · doi:10.1100/tsw.2002.228
  34. Sack, 1997, A role for Sp and nuclear receptor transcription factors in a cardiac hypertrophic growth program, Proc Natl Acad Sci U S A, 94, 6438, 10.1073/pnas.94.12.6438 · DOI · Paper page
  35. Ronkainen, 2011, Hypoxia and HIF-1 suppress SERCA2a expression in embryonic cardiac myocytes through two interdependent hypoxia response elements, J Mol Cell Cardiol, 50, 1008, 10.1016/j.yjmcc.2011.02.017 · DOI
  36. Williams, 2019, HIF-1 regulation of miR-29c impairs SERCA2 expression and cardiac contractility, Am J Physiol Heart Circ Physiol, 316, H554, 10.1152/ajpheart.00617.2018 · DOI
  37. Tsai, 2015, TNF-alpha down-regulates sarcoplasmic reticulum Ca(2)(+) ATPase expression and leads to left ventricular diastolic dysfunction through binding of NF-kappaB to promoter response element, Cardiovasc Res, 105, 318, 10.1093/cvr/cvv00 · doi:10.1093/cvr/cvv00
  38. Angrisano, 2014, Epigenetic switch at atp2a2 and myh7 gene promoters in pressure overload-induced heart failure, PLoS One, 9, e106024, 10.1371/journal.pone.0106024 · DOI
  39. Liu, 2018, Epigallocatechin-3 gallate prevents pressure overload-induced heart failure by up-regulating SERCA2a via histone acetylation modification in mice, PLoS One, 13, e0205123, 10.1371/journal.pone.0205123 · DOI
  40. Stenzig, 2016, DNA methylation in an engineered heart tissue model of cardiac hypertrophy: common signatures and effects of DNA methylation inhibitors, Basic Res Cardiol, 111, 9, 10.1007/s00395-015-0528-z · DOI
  41. Oh, 2019, Role of the PRC2-Six1-miR-25 signaling axis in heart failure, J Mol Cell Cardiol, 129, 58, 10.1016/j.yjmcc.2019.01.017 · DOI
  42. Zang, 2007, The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2, Nat Med, 13, 486, 10.1038/nm1569 · DOI · Paper page
  43. Carè, 2007, MicroRNA-133 controls cardiac hypertrophy, Nat Med, 13, 613, 10.1038/nm1582 · DOI · Paper page
  44. van Rooij, 2006, A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure, Proc Natl Acad Sci U S A, 103, 18255, 10.1073/pnas.0608791103 · DOI · Paper page
  45. Mendell, 2008, Miriad roles for the miR-17-92 cluster in development and disease, Cell, 133, 217, 10.1016/j.cell.2008.04.001 · DOI · Paper page
  46. Wahlquist, 2014, Inhibition of miR-25 improves cardiac contractility in the failing heart, Nature, 508, 531, 10.1038/nature13073 · DOI · Paper page
  47. Jeong, 2018, miR-25 tough decoy enhances cardiac function in heart failure, Mol Ther, 26, 718, 10.1016/j.ymthe.2017.11.014 · DOI
  48. Dirkx, 2013, Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure, Nat Cell Biol, 15, 1282, 10.1038/ncb2866 · DOI
  49. Bush, 2014, miR-25 in heart failure, Circ Res, 115, 610, 10.1161/CIRCRESAHA.114.304909 · DOI
  50. Li, 2014, MicroRNA-328 as a regulator of cardiac hypertrophy, Int J Cardiol, 173, 268, 10.1016/j.ijcard.2014.02.035 · doi:10.1016/j.ijcard.2014.02.035
  51. Lei, 2021, miR-132/212 impairs cardiomyocytes contractility in the failing heart by suppressing SERCA2a, Front Cardiovasc Med, 8, 592362, 10.3389/fcvm.2021.592362 · DOI
  52. Taubel, 2021, Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human phase 1b randomized, double-blind, placebo-controlled study, Eur Heart J, 42, 178, 10.1093/eurheartj/ehaa898 · DOI · Paper page
  53. Lu, 2019, RNA-based diagnostic and therapeutic strategies for cardiovascular disease, Nat Rev Cardiol, 16, 661, 10.1038/s41569-019-0218-x · DOI · Paper page
  54. Askarian-Amiri, 2011, SNORD-host RNA Zfas1 is a regulator of mammary development and a potential marker for breast cancer, RNA, 17, 878, 10.1261/rna.2528811 · DOI · Paper page
  55. Zhang, 2018, LncRNA ZFAS1 as a SERCA2a inhibitor to cause intracellular Ca(2+) overload and Contractile dysfunction in a mouse model of myocardial infarction, Circ Res, 122, 1354, 10.1161/CIRCRESAHA.117.312117 · DOI · Paper page
  56. Li, 2020, Circular RNAs cancer treatment, Trends Cancer, 6, 319, 10.1016/j.trecan.2020.01.012 · DOI · Paper page
  57. Han, 2020, The tumor-suppressive human circular RNA CircITCH sponges miR-330-5p to ameliorate doxorubicin-induced cardiotoxicity through upregulating SIRT6, survivin, and SERCA2a, Circ Res, 127, e108, 10.1161/CIRCRESAHA.119.316061 · DOI · Paper page
  58. Wegener, 1989, Phospholamban phosphorylation in intact ventricles. Phosphorylation of serine 16 and threonine 17 in response to beta-adrenergic stimulation, J Biol Chem, 264, 11468, 10.1016/S0021-9258(18)60487-9 · DOI · Paper page
  59. Karim, 2006, Phosphorylation-dependent conformational switch in spin-labeled phospholamban bound to SERCA, J Mol Biol, 358, 1032, 10.1016/j.jmb.2006.02.051 · DOI · Paper page
  60. MacDougall, 1991, Identification of the major protein phosphatases in mammalian cardiac muscle which dephosphorylate phospholamban, Eur J Biochem, 196, 725, 10.1111/j.1432-1033.1991.tb15871.x · DOI · Paper page
  61. Lygren, 2007, AKAP complex regulates Ca2+ re-uptake into heart sarcoplasmic reticulum, EMBO Rep, 8, 1061, 10.1038/sj.embor.7401081 · DOI · Paper page
  62. Carlson, 2022, AKAP18δ anchors and regulates CaMKII activity at phospholamban-SERCA2 and RYR, Circ Res, 130, 27, 10.1161/CIRCRESAHA.120.317976 · DOI
  63. Singh, 2011, The large isoforms of A-kinase anchoring protein 18 mediate the phosphorylation of inhibitor-1 by protein kinase A and the inhibition of protein phosphatase 1 activity, Mol Pharmacol, 79, 533, 10.1124/mol.110.065425 · DOI
  64. del Monte, 2002, Targeting phospholamban by gene transfer in human heart failure, Circulation, 105, 904, 10.1161/hc0802.105564 · DOI · Paper page
  65. Minamisawa, 1999, Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy, Cell, 99, 313, 10.1016/s0092-8674(00)81662-1 · DOI · Paper page
  66. Schwinger, 1999, Reduced Ca(2+)-sensitivity of SERCA 2a in failing human myocardium due to reduced serin-16 phospholamban phosphorylation, J Mol Cell Cardiol, 31, 479, 10.1006/jmcc.1998.0897 · DOI · Paper page
  67. El-Armouche, 2004, Decreased protein and phosphorylation level of the protein phosphatase inhibitor-1 in failing human hearts, Cardiovasc Res, 61, 87, 10.1016/j.cardiores.2003 · doi:10.1016/j.cardiores.2003
  68. Carr, 2002, Type 1 phosphatase, a negative regulator of cardiac function, Mol Cell Biol, 22, 4124, 10.1128/MCB.22.12.4124-4135.2002 · DOI · Paper page
  69. Oh, 2013, Decoy peptides targeted to protein phosphatase 1 inhibit dephosphorylation of phospholamban in cardiomyocytes, J Mol Cell Cardiol, 56, 63, 10.1016/j.yjmcc.2012.12.005 · DOI
  70. Pathak, 2005, Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1, Circ Res, 96, 756, 10.1161/01.RES.0000161256.85833.fa · DOI · Paper page
  71. Watanabe, 2017, Protein phosphatase inhibitor-1 gene therapy in a swine model of nonischemic heart failure, J Am Coll Cardiol, 70, 1744, 10.1016/j.jacc.2017.08.013 · DOI
  72. Schmitt, 2003, Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban, Science, 299, 1410, 10.1126/science.1081578 · DOI · Paper page
  73. Haghighi, 2003, Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human, J Clin Invest, 111, 869, 10.1172/JCI17892 · DOI · Paper page
  74. Nelson, 2016, A peptide encoded by a transcript annotated as long noncoding RNA enhances SERCA activity in muscle, Science, 351, 271, 10.1126/science.aad4076 · DOI · Paper page
  75. Singh, 2019, Newly discovered micropeptide regulators of SERCA form oligomers but bind to the pump as monomers, J Mol Biol, 431, 4429, 10.1016/j.jmb.2019.07.037 · DOI · Paper page
  76. Fisher, 2021, Dwarf open Reading frame (DWORF) is a direct activator of the sarcoplasmic reticulum calcium pump SERCA, eLife, 10, e65545, 10.7554/eLife.65545 · DOI
  77. Cleary, 2022, Inhibitory and stimulatory micropeptides preferentially bind to different conformations of the cardiac calcium pump, J Biol Chem, 298, 102060, 10.1016/j.jbc.2022.102060 · DOI · Paper page
  78. Makarewich, 2018, The DWORF micropeptide enhances contractility and prevents heart failure in a mouse model of dilated cardiomyopathy, eLife, 7, e38319, 10.7554/eLife.38319 · DOI · Paper page
  79. Makarewich, 2020, Gene therapy with the DWORF micropeptide attenuates cardiomyopathy in mice, Circ Res, 127, 1340, 10.1161/CIRCRESAHA.120.317156 · DOI · Paper page
  80. Morales, 2023, Dwarf open reading frame (DWORF) gene therapy ameliorated duchenne muscular dystrophy cardiomyopathy in aged mdx mice, J Am Heart Assoc, 12, e027480, 10.1161/JAHA.122.027480 · DOI
  81. Weiss, 1976, Hemodynamic determinants of the time-course of fall in canine left ventricular pressure, J Clin Invest, 58, 751, 10.1172/JCI108522 · DOI · Paper page
  82. Arvanitis, 2007, Histidine-rich ca-binding protein interacts with sarcoplasmic reticulum ca-ATPase, Am J Physiol Heart Circ Physiol, 293, H1581, 10.1152/ajpheart.00278.2007 · DOI
  83. Kiewitz, 2003, Ca2+-dependent interaction of S100A1 with the sarcoplasmic reticulum Ca2+-ATPase2a and phospholamban in the human heart, Biochem Biophys Res Commun, 306, 550, 10.1016/s0006-291x(03)00987-2 · DOI
  84. Arvanitis, 2008, The Ser96Ala variant in histidine-rich calcium-binding protein is associated with life-threatening ventricular arrhythmias in idiopathic dilated cardiomyopathy, Eur Heart J, 29, 2514, 10.1093/eurheartj/ehn328 · DOI
  85. Brinks, 2011, S100a1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes, J Am Coll Cardiol, 58, 966, 10.1016/j.jacc.2011.03.054 · DOI
  86. Soltani, 2021, Elevated serum levels of S100A1 and zinc alpha2-glycoprotein in patients with heart failure, Nutr Metab Cardiovasc Dis, 31, 162, 10.1016/j.numecd.2020.07.029 · DOI
  87. Cuffe, 2002, Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial, JAMA, 287, 1541, 10.1001/jama.287.12.1541 · DOI · Paper page
  88. Sun, 2007, Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice, Cell Signal, 19, 1765, 10.1016/j.cellsig.2007.03.012 · doi:10.1016/j.cellsig.2007.03.012
  89. Beca, 2013, Phosphodiesterase type 3A regulates basal myocardial contractility through interacting with sarcoplasmic reticulum calcium ATPase type 2a signaling complexes in mouse heart, Circ Res, 112, 289, 10.1161/CIRCRESAHA.111.300003 · DOI
  90. Ahmad, 2015, Regulation of sarcoplasmic reticulum Ca2+ ATPase 2 (SERCA2) activity by phosphodiesterase 3A (PDE3A) in human myocardium: phosphorylation-dependent interaction of PDE3A1 with SERCA2, J Biol Chem, 290, 6763, 10.1074/jbc.M115.638585 · DOI
  91. Dhalla, 1996, Role of oxidative stress in transition of hypertrophy to heart failure, J Am Coll Cardiol, 28, 506, 10.1016/0735-1097(96)00140-4 · DOI · Paper page
  92. Lancel, 2010, Oxidative posttranslational modifications mediate decreased SERCA activity and myocyte dysfunction in galphaq-overexpressing mice, Circ Res, 107, 228, 10.1161/CIRCRESAHA.110.217570 · DOI
  93. Radi, 2013, Protein tyrosine nitration: biochemical mechanisms and structural basis of functional effects, Acc Chem Res, 46, 550, 10.1021/ar300234c · DOI · Paper page
  94. Knyushko, 2005, 3-Nitrotyrosine Modification of SERCA2a in the aging heart: a distinct signature of the cellular redox environment, Biochemistry, 44, 13071, 10.1021/bi051226n · DOI
  95. Gorski, 2019, Role of SIRT1 in modulating acetylation of the sarco-endoplasmic Reticulum Ca(2+)-ATPase in heart failure, Circ Res, 124, e63, 10.1161/CIRCRESAHA.118.313865 · DOI
  96. Gorski, 2023, Identification and characterization of p300-mediated lysine residues in cardiac SERCA2a, Int J Mol Sci, 24, 3502, 10.3390/ijms24043502 · DOI
  97. Zhang, 2022, Structural basis of the conformational and functional regulation of human SERCA2b, the ubiquitous endoplasmic reticulum calcium pump, Bioessays, 44, e2200052, 10.1002/bies.202200052 · DOI
  98. Narita, 2019, Author correction: functions and mechanisms of non-histone protein acetylation, Nat Rev Mol Cell Biol, 20, 508, 10.1038/s41580-019-0156-9 · DOI
  99. Adachi, 2004, S-Glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide, Nat Med, 10, 1200, 10.1038/nm1119 · DOI · Paper page
  100. Tong, 2008, High glucose oxidizes SERCA cysteine-674 and prevents inhibition by nitric oxide of smooth muscle cell migration, J Mol Cell Cardiol, 44, 361, 10.1016/j.yjmcc.2007.10.022 · DOI
  101. Paolocci, 2003, Positive inotropic and lusitropic effects of HNO/NO- in failing hearts: independence from beta-adrenergic signaling, Proc Natl Acad Sci U S A, 100, 5537, 10.1073/pnas.0937302100 · DOI · Paper page
  102. Tocchetti, 2007, Nitroxyl improves cellular heart function by directly enhancing cardiac sarcoplasmic reticulum Ca2+ cycling, Circ Res, 100, 96, 10.1161/01.RES.0000253904.53601.c9 · DOI · Paper page
  103. Goodman, 2020, Redox-resistant SERCA [sarco(endo)plasmic Reticulum calcium ATPase] attenuates oxidant-stimulated mitochondrial calcium and apoptosis in cardiac myocytes and pressure overload-induced myocardial failure in mice, Circulation, 142, 2459, 10.1161/CIRCULATIONAHA.120.048183 · DOI
  104. Sivakumaran, 2013, HNO enhances SERCA2a activity and cardiomyocyte function by promoting redox-dependent phospholamban oligomerization, Antioxid Redox Signal, 19, 1185, 10.1089/ars.2012.5057 · DOI
  105. Kho, 2011, SUMO1-dependent modulation of SERCA2a in heart failure, Nature, 477, 601, 10.1038/nature10407 · DOI · Paper page
  106. Kim, 2015, Involvement of activated SUMO-2 conjugation in cardiomyopathy, Biochim Biophys Acta, 1852, 1388, 10.1016/j.bbadis.2015.03.013 · DOI
  107. Gupta, 2014, Sumo E2 enzyme UBC9 is required for efficient protein quality control in cardiomyocytes, Circ Res, 115, 721, 10.1161/CIRCRESAHA.115.304760 · DOI
  108. Tilemann, 2013, SUMO-1 gene transfer improves cardiac function in a large-animal model of heart failure, Sci Transl Med, 5, 211ra159, 10.1126/scitranslmed.3006487 · DOI
  109. Lee, 2014, The role of SUMO-1 in cardiac oxidative stress and hypertrophy, Antioxid Redox Signal, 21, 1986, 10.1089/ars.2014.5983 · DOI
  110. Oh, 2018, miR-146a suppresses SUMO1 expression and induces cardiac dysfunction in maladaptive hypertrophy, Circ Res, 123, 673, 10.1161/CIRCRESAHA.118.312751 · DOI
  111. Kho, 2015, Small-molecule activation of SERCA2a SUMOylation for the treatment of heart failure, Nat Commun, 6, 7229, 10.1038/ncomms8229 · DOI
  112. Lyon, 2020, Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device—the SERCA-LVAD TRIAL, Gene Ther, 27, 579, 10.1038/s41434-020-0171-7 · DOI
  113. Asokan, 2010, Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle, Nat Biotechnol, 28, 79, 10.1038/nbt.1599 · DOI · Paper page
  114. Cornea, 2013, High-throughput FRET assay yields allosteric SERCA activators, J Biomol Screen, 18, 97, 10.1177/1087057112456878 · DOI · Paper page
  115. Dahl, 2017, A new target for Parkinson’s disease: small molecule SERCA activator CDN1163 ameliorates dyskinesia in 6-OHDA-lesioned rats, Bioorg Med Chem, 25, 53, 10.1016/j.bmc.2016.10.008 · doi:10.1016/j.bmc.2016.10.008
  116. Kang, 2016, Small molecular allosteric activator of the sarco/endoplasmic Reticulum Ca2+-ATPase (SERCA) attenuates diabetes and metabolic disorders, J Biol Chem, 291, 5185, 10.1074/jbc.M115.705012 · DOI · Paper page
  117. Nogami, 2021, Pharmacological activation of SERCA ameliorates dystrophic phenotypes in dystrophin-deficient mdx mice, Hum Mol Genet, 30, 1006, 10.1093/hmg/ddab100 · doi:10.1093/hmg/ddab100
  118. Kaneko, 2017, A pyridone derivative activates SERCA2a by attenuating the inhibitory effect of phospholamban, Eur J Pharmacol, 814, 1, 10.1016/j.ejphar.2017.07.035 · DOI
  119. Gobbini, 2010, Novel analogues of istaroxime, a potent inhibitor of Na(+), K(+)-ATPase: synthesis, structure-activity relationship and 3D-quantitative structure-activity relationship of derivatives at position 6 on the androstane scaffold, Bioorg Med Chem, 18, 4275, 10.1016/j.bmc.2010.04.095 · DOI
  120. Micheletti, 2007, Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure, Am J Cardiol, 99, 24A, 10.1016/j.amjcard.2006.09.003 · DOI
  121. Ferrandi, 2013, Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition, Br J Pharmacol, 169, 1849, 10.1111/bph.12278 · DOI
  122. Carubelli, 2020, Treatment with 24 h istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial, Eur J Heart Fail, 22, 1684, 10.1002/ejhf.1743 · DOI
  123. Metra, 2022, Safety and efficacy of istaroxime in patients with acute heart failure-related pre-cardiogenic shock—a multicentre, randomized, double-blind, placebo-controlled, parallel group study (SEISMiC), Eur J Heart Fail, 24, 1967, 10.1002/ejhf.2629 · doi:10.1002/ejhf.2629
  124. Sarma, 2023, SERCA2a Agonist effects on cardiac performance during exercise in heart failure with preserved ejection fraction, JACC Heart Fail, 11, 760, 10.1016/j.jchf.2023.02.006 · doi:10.1016/j.jchf.2023.02.006
  125. Luraghi, 2022, Highly selective SERCA2a activators: preclinical development of a congeneric group of first-in-class drug leads against heart failure, J Med Chem, 65, 7324, 10.1021/acs.jmedchem.2c00347 · DOI
  126. Arici, 2023, Istaroxime metabolite PST3093 selectively stimulates SERCA2a and reverses disease-induced changes in cardiac function, J Pharmacol Exp Ther, 384, 231, 10.1124/jpet.122.001335 · doi:10.1124/jpet.122.001335
  127. Scully, 2019, Caplacizumab treatment for acquired thrombotic thrombocytopenic Purpura, N Engl J Med, 380, 335, 10.1056/NEJMoa1806311 · DOI · Paper page
  128. De Genst, 2022, Blocking phospholamban with VHH intrabodies enhances contractility and relaxation in heart failure, Nat Commun, 13, 3018, 10.1038/s41467-022-29703-9 · DOI
  129. Skogestad, 2023, Disruption of phosphodiesterase 3A binding to SERCA2 increases SERCA2 activity and reduces mortality in mice with chronic heart failure, Circulation, 147, 1221, 10.1161/CIRCULATIONAHA.121.054168 · DOI
  130. Liu, 2021, Rg3 promotes the SUMOylation of SERCA2a and corrects cardiac dysfunction in heart failure, Pharmacol Res, 172, 105843, 10.1016/j.phrs.2021.105843 · DOI
  131. Wang, 2021, Dietary luteolin: a narrative review focusing on its pharmacokinetic properties and effects on glycolipid metabolism, J Agric Food Chem, 69, 1441, 10.1021/acs.jafc.0c08085 · DOI · Paper page
  132. Hu, 2017, Luteolin improves cardiac dysfunction in heart failure rats by regulating sarcoplasmic reticulum Ca(2+)-ATPase 2a, Sci Rep, 7, 41017, 10.1038/srep41017 · DOI
  133. Du, 2018, Luteolin modulates SERCA2a leading to attenuation of myocardial ischemia/reperfusion injury via sumoylation at lysine 585 in mice, Cell Physiol Biochem, 45, 883, 10.1159/000487283 · DOI
  134. Lamberti, 2018, NQO1 induction mediated by photodynamic therapy synergizes with beta-lapachone-halogenated derivative against melanoma, Biomed Pharmacother, 108, 1553, 10.1016/j.biopha.2018.09.159 · DOI
  135. Sulaiman, 2010, Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy, Am J Physiol Heart Circ Physiol, 298, H833, 10.1152/ajpheart.00418.2009 · DOI · Paper page
  136. Dong, 2014, Resveratrol ameliorates cardiac dysfunction induced by pressure overload in rats via structural protection and modulation of Ca(2+) cycling proteins, J Transl Med, 12, 323, 10.1186/s12967-014-0323-x · DOI
  137. Gal, 2020, Resveratrol improves heart function by moderating inflammatory processes in patients with systolic heart failure, Antioxidants (Basel, 9, 1108, 10.3390/antiox9111108 · DOI
  138. O'Donnell, 2008, Limited functional and metabolic improvements in hypertrophic and healthy rat heart overexpressing the skeletal muscle isoform of SERCA1 by adenoviral gene transfer in vivo, Am J Physiol Heart Circ Physiol, 295, H2483, 10.1152/ajpheart.01023.2008 · DOI
  139. Teucher, 2004, Excessive sarcoplasmic/endoplasmic reticulum Ca2+-ATPase expression causes increased sarcoplasmic reticulum Ca2+ uptake but decreases myocyte shortening, Circulation, 110, 3553, 10.1161/01.CIR.0000145161.48545.B3 · DOI
  140. Carvalho, 2006, Enhanced calcium mobilization in rat ventricular myocytes during the onset of pressure overload-induced hypertrophy, Am J Physiol Heart Circ Physiol, 291, H1803, 10.1152/ajpheart.01345.2005 · DOI

Cited by

See all 54

Metadata

Authors
Kho, C.
Venue
Frontiers in Cardiovascular Medicine
Published
2023-07-18
Volume
10
ISSN
2297-055X
Cited by
54
References
12

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting calcium regulators as therapy for heart failure: focus on the sarcoplasmic reticulum Ca-ATPase pump. https://app.cochat.ai/papers/10.3389/fcvm.2023.1185261
The paper
Kho, C. (2023). Targeting calcium regulators as therapy for heart failure: focus on the sarcoplasmic reticulum Ca-ATPase pump. Frontiers in Cardiovascular Medicine. https://doi.org/10.3389/fcvm.2023.1185261

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.